ClinicalTrials.gg
CompletedNCT01994473SEP-363856Updated Jun 26, 2024

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

A Phase 1 interventional study of SEP-363856 and Placebo in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
16th of 23
48 · median 83
Started
2013
the only one that year
Phase 1
11 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 16th largest by enrollment, is the only one that started in 2013, is one of 11 in phase 1, and was the 2nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.

Read the detailed description

This multicenter study will be conducted in 2 parts (Part 1 and 2). Part 1 of the study is a multicenter, randomized, single-blind, placebo-controlled portion, ascending multiple oral dose study designed to evaluate the safety, tolerability, and PK of ascending multiple oral doses of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia. Part 1 This study will determine the MTD for once-daily multiple oral administration of SEP-363856, and characterize the plasma and urine PK profiles of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia. The effect of SEP-363856 on the PANSS, CGI-S, and CDSS scales will also be assessed. For each of the dose-escalation cohorts, 12 subjects (9 active subjects and 3 placebo subjects) will be dosed for 7 consecutive days with serial collection of PK blood samples after the first and last doses, and daily collection of trough PK blood samples. An attempt will be made to have at least one-third of subjects in each cohort be female. Part 2 of the study is an open-label safety and tolerability study designed to gain longer-term safety and tolerability data for 75 mg SEP-363856 given once-daily for 28 days in male and female subjects with schizophrenia. The effect of SEP-363856 on the PANSS, CGI-S, and CDSS scales will also be assessed. In Part 2, 16 subjects will be dosed.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must give written and privacy authorization (Healthcare Insurance, Portability, and Accountability Act of 1996) prior to participation in the study. Female subjects of childbearing potential1 and male subjects must agree to requirements outlined in the informed consent form.
  2. Subject must be willing and able to comply with the study procedures and visit schedules and must be able to follow verbal and written instructions.
  3. Male or female subject between 18 to 55 years of age (inclusive) at the time of consent.
  4. Subject's (BMI) must be at least 19.5 kg/m2 but no more than 37 kg/m2.
  5. Female subject must have a negative serum pregnancy test at screening.
  6. Female subjects of childbearing potential1 must agree to avoid pregnancy and use acceptable methods of birth control from at least 60 days prior to screening and for at least 90 days after the last study drug administration.
  7. Male subjects with female partner(s) of childbearing potential1 must agree to avoid fathering a child and use acceptable methods of birth control (see Section 24) from screening until at least 90 days after the last study drug administration.
  8. Subject must meet the Fourth Edition; Text Revision (DSM-IV-TR) criteria for a primary diagnosis of schizophrenia with the following subtypes: disorganized (295.10), catatonic type (295.20), paranoid (295.30), residual (295.60), or undifferentiated (295.90); and in the opinion of the Investigator has been clinically stable for the past 6 months.
  9. Subject must have a CGI-S score ≤ 4 (normal to moderately ill) at screening.
  10. Subject must have a PANSS total score ≤ 80 at screening.
  11. Subject must have a score of ≤ 4 (normal to moderate) on the following PANSS items at screening:

    • P7 (hostility)
    • G8 (uncooperativeness)
  12. Subject must be able and agree to remain off prior antipsychotic medication from clinic admission through Day 10
  13. Subject must have normal to mild symptoms on all individual items of the MSAS (\< 2) and AIMS (\< 3), and the clinical global assessment item of the BARS (\< 3).
  14. Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, physical examination, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, serum prolactin, and glycosylated ()], and a 12-lead .
  15. Subject must be willing to stay within the clinic for the required period and return for follow-up visits.
  16. Subject must possess an educational level and degree of understanding of English that enables them to communicate suitably with the Investigator and study coordinator.
  17. Subject must agree to comply with all restrictions for the required length of time

Exclusion criteria

Exclusion Criteria:

  1. Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
  2. Subject has participated in an drug study and received investigational drug within 30 days (or longer if the half-life is known to be ≥ 150 hours) prior to the screening visit, or who is currently participating in another clinical study. Subject has previously received study drug.
  3. Subject has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:

    1. Hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease (except for untreated, asymptomatic, seasonal allergies at time of dosing).
    2. History of cancer or significant neoplasm.
    3. Disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection, or any surgical procedure) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
    4. Known or suspected excessive alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the screening visit or a positive breath alcohol test at screening.
    5. Subject has a clinically significant abnormal 12-lead that may jeopardize the subject's ability to complete the study or a screening 12-lead ECG demonstrating any one of the following: heart rate > 100 beats per minute, QRS > 120 ms, QTinterval corrected for heart rate using Fridericia's formula () > 450 ms (males), QTcF > 470 ms (females), or PR > 220 ms.
  4. Female subject who is pregnant or lactating.
  5. Subject has a presence or history of a medically diagnosed, clinically significant psychiatric disorder (including mental retardation, schizoaffective disorder, schizophreniform disorder, psychotic depression, and bipolar disorder) other than schizophrenia.
  6. Subject experienced an acute exacerbation of psychosis within the last 3 months or experienced an acute exacerbation of psychosis requiring hospitalization within the last 6 months.
  7. Subject experienced an acute exacerbation of psychosis requiring change in antipsychotic medication (with reference to drug or dose) within the last 3 months.
  8. Subject has a diagnosis or history of substance dependence (except nicotine ≤ 1 pack/day) or substance abuse (except cannabis) according to DSM IV-TR criteria ≤ 3 months prior to screening or a positive urine drug screen (except benzodiazepines) at screening.
  9. Subject is at significant risk of harming him/herself or others according to the Investigator's judgment.
  10. Subject has had past episodes of significant extrapyramidal symptoms (EPS) under current medication that required dose modification or the addition of anti-Parkinson's treatment within the last 6 months.
  11. Subject is currently or has within 1 year before entering the study been treated with a depot antipsychotic medication.
  12. Subject is under forced treatment.
  13. Subject is taking aripiprazole at screening. Subject takes or has taken other disallowed recent or concomitant medications (see Section 10.5). Subjects must taper off antipsychotic medications by Day -1.
  14. Subject has a history of allergic reaction to any medication or has a known or suspected sensitivity to any substance that is contained in the formulation.
  15. Subject has any clinically significant abnormal laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin) (Note: abnormal findings that may be clinically significant or of questionable significance will be discussed with the Medical Monitor prior to including subject).
  16. Subject has a history of hospitalization within 45 days prior to the screening visit.
  17. Subject has a positive test for surface antigen or antibody at screening.
  18. Subject has a positive test for Type 1 or 2 (HIV-1 or HIV-2) at screening, or subject is known to have tested positive for Human Immunodeficiency Virus (HIV).
  19. Subject has abnormal hepatic function tests ( [AST], alanine aminotransferase [ALT], ) or renal function (estimated [CrCl] \< 60 mL/min based on serum creatinine using Modification of Diet in Renal Disease []-glomerular filtration rate [GFR] method) at screening.
  20. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
  21. Subject consumes more than 300 mg of caffeine per day (5 cups of coffee or equivalent in caffeinated beverages).
  22. Subject has used disallowed prescription (see Sections 10.5.1 and 10.5.2) or disallowed nonprescription drugs, vitamins, or dietary or herbal supplements within 14 days prior to dosing or anticipates the need for any disallowed medication during their participation in this study [exception: female subjects who are taking oral, patch, or intrauterine device (IUD) hormonal , or progestin implant or injection]. Enzyme-modulators (inclusive of enzyme-inhibitors and -inducers) including herbal supplements (eg, Metabolife™) must be discontinued 30 days prior to the first dose of study drug.
  23. Subject is a staff member or the relative of a staff member.
  24. Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    SEP-363856

    Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.

    Drug: SEP-363856

  • Placebo comparator
    Placebo

    An oral of matched placebo

    Drug: Placebo

  • Experimental
    SEP-363856 Open Label

    75 mg SEP-363856 given once-daily

    Drug: SEP-363856 Open Label

Interventions

  • SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg

  • DrugPlacebo

    single oral dose placebo

  • 75 mg SEP-363856 given once-daily

06

What researchers measure

Primary outcomes

  1. Frequency of AEs, SAEs, and AEs resulting in study discontinuation in Parts 1 and 2.

    Time frame: Up to 57 days

  2. Absolute values and changes from baseline in clinical laboratory tests, vital signs, 12-lead ECGs, and findings from neurological examinations in Parts 1 and 2

    Absolute values and changes from baseline in clinical laboratory tests (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin), vital signs (blood pressure \[supine and standing\], heart rate \[supine and standing\], respiration rate, and body temperature), 12-lead ECGs, and findings from neurological examinations in Parts 1 and 2

    Time frame: Up to 57 days

  3. Frequency of subjects with suicidal ideation or suicidal behavior using the Columbia-Suicide Severity Rating Scale (C-SSRS) in Parts 1 and 2.

    Time frame: Up to 57 days

Secondary outcomes

  1. Plasma SEP-363856 and metabolite SEP-363854 maximum observed concentration (Cmax)

    Time frame: Part 1, Day 1 (following first dose)

  2. Plasma metabolite to parent ratio for Cmax (MRCmax) and AUC0-24 (MRAUC0-24).

    Time frame: Part 1, Day 1 (following first dose)

  3. Plasma SEP-363856 and metabolite SEP-363854 Cmax, tmax, AUC0-tau, terminal elimination half-life (t1/2), and accumulation ratios based on Cmax (RCmax), and AUC0-tau (RAUC0-tau).

    Time frame: Part 1, Day 7 (following last dose)

  4. Plasma metabolite to parent ratio for Cmax (MRCmax) and AUC0-tau (MRAUC0-tau).

    Time frame: Part 1, Day 7 (following last dose)

  5. Plasma SEP-363856 steady-state apparent volume of distribution (Vss/F).

    Time frame: Day 7 (following last dose)

  6. SEP-363856 and metabolite SEP-363854 renal clearance (CLR) and fraction excreted (fe) expressed as percent of administered dose.

    Time frame: Part 1, Day 7 (following last dose)

  7. SEP-363856 and SEP-363854 amount excreted (Ae) in urine.

    Time frame: Part 1, Day 7 (following last dose)

  8. Plasma SEP-363856 and metabolite SEP-363854 time of occurrence of Cmax (tmax)

    Time frame: Part 1, Day 1 (following first dose)

  9. Plasma SEP-363856 and metabolite SEP-363854 area under the concentration-time curve (AUC0-24).

    Time frame: Part 1, Day 1 (following first dose)

  10. Plasma SEP-363856 steady-state apparent clearance (CLss/F)

    Time frame: Part 1, Day 7 (following last dose)

  11. Plasma SEP-363856 and metabolite SEP-363854 Cmax, tmax, and AUC0-24

    Time frame: Part 2, Day 13

07

Study locations

2 sites
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 25, 2013
Start
Oct 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01994473
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Oct 2013
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Jun 26, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion